Opinion
Video
The EMBARK trial investigating enzalutamide in NM CSPC
Prostate cancer experts analyze the EMBARK trial, emphasizing the potential impact of an androgen receptor inhibitor in the treatment of non-metastatic castration-sensitive prostate cancer.
EP: 1.Testing Principes and Benefits of Early Intervention in Castration-Sensitive Prostate Cancer
EP: 2.Risk Stratification and Prognostic Markers in castration-sensitive prostate cancer
EP: 3.Evolving Treatment Paradigm and NCCN Guideline Updates
Now Viewing
EP: 4.The EMBARK trial investigating enzalutamide in NM CSPC
EP: 5.The Role of PSA Doubling Time in Risk Assessment
EP: 6.Patient Case 1: Non-Metastatic CSPC with Rapidly Doubling PSA
EP: 7.Patient Case 2: Metastatic CSPC
EP: 8.Final Thoughts on CSPC
- Dr. Efstathiou asks Dr. Freedland: Enzalutamide is currently the only androgen receptor inhibitor approved for non-metastatic CSPC. Can you summarize the key data from the EMBARK trial supporting its use in this setting?
- Please comment of the high risk study population evaluated in the EMBARK trial
- What were the primary endpoints and efficacy findings from the EMBARK trial? Please also comment on your impressions of the monotherapy arm.
- What are your impressions of the safety data from EMBARK?
Related Videos
Related Content
